198 related articles for article (PubMed ID: 27888016)
21. Lymphohematopoietic graft-vs.-host reactions can be induced without graft-vs.-host disease in murine mixed chimeras established with a cyclophosphamide-based nonmyeloablative conditioning regimen.
Pelot MR; Pearson DA; Swenson K; Zhao G; Sachs J; Yang YG; Sykes M
Biol Blood Marrow Transplant; 1999; 5(3):133-43. PubMed ID: 10392959
[TBL] [Abstract][Full Text] [Related]
22. Ixazomib for the treatment of multiple myeloma.
Gentile M; Offidani M; Vigna E; Corvatta L; Recchia AG; Morabito L; Morabito F; Gentili S
Expert Opin Investig Drugs; 2015; 24(9):1287-98. PubMed ID: 26138345
[TBL] [Abstract][Full Text] [Related]
23. [Role of TJU103 in prevention of graft-versus-host disease after allogeneic stem cell transplantation in mice].
Wang SB; Guo KY; Hu DM; Yin B
Nan Fang Yi Ke Da Xue Xue Bao; 2006 Jun; 26(6):810-3. PubMed ID: 16793606
[TBL] [Abstract][Full Text] [Related]
24. [Pharmacological characteristics and clinical study results of the oral proteasome inhibitor ixazomib (NINLARO
Machida M; Fukunaga S; Hara T
Nihon Yakurigaku Zasshi; 2018; 151(4):166-178. PubMed ID: 29628465
[TBL] [Abstract][Full Text] [Related]
25. Keratinocyte growth factor administered before conditioning ameliorates graft-versus-host disease after allogeneic bone marrow transplantation in mice.
Panoskaltsis-Mortari A; Lacey DL; Vallera DA; Blazar BR
Blood; 1998 Nov; 92(10):3960-7. PubMed ID: 9808590
[TBL] [Abstract][Full Text] [Related]
26. Ixazomib for Treatment of Refractory Chronic Graft-versus-Host Disease: A Chronic GVHD Consortium Phase II Trial.
Pidala J; Bhatt VR; Hamilton B; Pusic I; Wood WA; Onstad L; Hall AM; Storer B; Lee SJ
Biol Blood Marrow Transplant; 2020 Sep; 26(9):1612-1619. PubMed ID: 32464285
[TBL] [Abstract][Full Text] [Related]
27. [Influence of mouse genetic engineering regulatory T cells infusion on post-allogeneic bone marrow transplantation acute graft-versus-host disease in mice].
Cao J; Li L; Chen C; Zeng LY; Li ZY; Pan XY; Xu KL
Zhonghua Xue Ye Xue Za Zhi; 2011 Feb; 32(2):83-8. PubMed ID: 21429372
[TBL] [Abstract][Full Text] [Related]
28. CD6+ T cell depleted allogeneic bone marrow transplantation from genotypically HLA nonidentical related donors.
Soiffer RJ; Mauch P; Fairclough D; Alyea E; Anderson K; Fisher D; Freedman A; Bartlett-Pandite L; Robertson M; Schlossman R; Gollob J; Marcus K; Murray C; Kuhlman C; Freeman A; Nadler L; Ritz J
Biol Blood Marrow Transplant; 1997 Apr; 3(1):11-7. PubMed ID: 9209736
[TBL] [Abstract][Full Text] [Related]
29. Haploidentical T Cell-Replete Transplantation with Post-Transplantation Cyclophosphamide for Patients in or above the Sixth Decade of Age Compared with Allogeneic Hematopoietic Stem Cell Transplantation from an Human Leukocyte Antigen-Matched Related or Unrelated Donor.
Blaise D; Fürst S; Crocchiolo R; El-Cheikh J; Granata A; Harbi S; Bouabdallah R; Devillier R; Bramanti S; Lemarie C; Picard C; Chabannon C; Weiller PJ; Faucher C; Mohty B; Vey N; Castagna L
Biol Blood Marrow Transplant; 2016 Jan; 22(1):119-24. PubMed ID: 26341397
[TBL] [Abstract][Full Text] [Related]
30. Delayed administration of ixazomib modifies the immune response and prevents chronic graft-versus-host disease.
Ramos TL; García-Guerrero E; Caballero-Velázquez T; Rodríguez-Gil A; Caracuel-García R; Nufer M; Robles-Frías MJ; Barbado MV; Pérez-Simón JA
Bone Marrow Transplant; 2021 Dec; 56(12):3049-3058. PubMed ID: 34556806
[TBL] [Abstract][Full Text] [Related]
31. Integrated nonclinical and clinical risk assessment of the investigational proteasome inhibitor ixazomib on the QTc interval in cancer patients.
Gupta N; Huh Y; Hutmacher MM; Ottinger S; Hui AM; Venkatakrishnan K
Cancer Chemother Pharmacol; 2015 Sep; 76(3):507-16. PubMed ID: 26141494
[TBL] [Abstract][Full Text] [Related]
32. Suppression of graft-versus-host disease and amplification of graft-versus-tumor effects by activated natural killer cells after allogeneic bone marrow transplantation.
Asai O; Longo DL; Tian ZG; Hornung RL; Taub DD; Ruscetti FW; Murphy WJ
J Clin Invest; 1998 May; 101(9):1835-42. PubMed ID: 9576746
[TBL] [Abstract][Full Text] [Related]
33. Control of mouse graft-versus-host disease following allogeneic bone marrow transplantation by blocking the CD28/B7 signaling pathway with lentiviral vector-mediated RNA interference.
Sang W; Zhou C; Cheng N; Li Z; Zeng L; Xu K
Immunol Lett; 2011 May; 136(2):194-202. PubMed ID: 21277900
[TBL] [Abstract][Full Text] [Related]
34. Ex vivo treatment of murine splenocyte-supplemented bone marrow inocula with mafosfamide prior to allogeneic transplantation in an attempt to prevent lethal graft-versus-host disease without compromising engraftment.
Kohn FR; Sladek NE
Immunopharmacol Immunotoxicol; 1988; 10(3):387-98. PubMed ID: 3058776
[TBL] [Abstract][Full Text] [Related]
35. A metalloproteinase inhibitor prevents acute graft-versus-host disease while preserving the graft-versus-leukaemia effect of allogeneic bone marrow transplantation.
Hattori K; Hirano T; Miyajima H; Yamakawa N; Ikeda S; Yoshino K; Tateno M; Oshimi K; Kayagaki N; Yagita H; Okumura K
Br J Haematol; 1999 Apr; 105(1):303-12. PubMed ID: 10233398
[TBL] [Abstract][Full Text] [Related]
36. Expanded donor natural killer cell and IL-2, IL-15 treatment efficacy in allogeneic hematopoietic stem cell transplantation.
Chen G; Wu D; Wang Y; Cen J; Feng Y; Sun A; Tang X; Chang H; Zhu Z
Eur J Haematol; 2008 Sep; 81(3):226-35. PubMed ID: 18573173
[TBL] [Abstract][Full Text] [Related]
37. A metalloproteinase inhibitor prevents acute graft-versus-host disease while preserving the graft-versus-leukaemia effect of allogeneic bone marrow transplantation.
Hattori K; Hirano T; Oshimi K; Yagita H; Okumura K
Leuk Lymphoma; 2000 Aug; 38(5-6):553-61. PubMed ID: 10953977
[TBL] [Abstract][Full Text] [Related]
38. Ixazomib-induced cutaneous necrotizing vasculitis.
Alloo A; Khosravi H; Granter SR; Jadeja SM; Richardson PG; Castillo JJ; LeBoeuf NR
Support Care Cancer; 2018 Jul; 26(7):2247-2250. PubMed ID: 29392482
[TBL] [Abstract][Full Text] [Related]
39. A phase I study to assess the mass balance, excretion, and pharmacokinetics of [
Gupta N; Zhang S; Pusalkar S; Plesescu M; Chowdhury S; Hanley MJ; Wang B; Xia C; Zhang X; Venkatakrishnan K; Shepard DR
Invest New Drugs; 2018 Jun; 36(3):407-415. PubMed ID: 28932928
[TBL] [Abstract][Full Text] [Related]
40. Effects of T cell depletion in radiation bone marrow chimeras. I. Evidence for a donor cell population which increases allogeneic chimerism but which lacks the potential to produce GVHD.
Sykes M; Sheard M; Sachs DH
J Immunol; 1988 Oct; 141(7):2282-8. PubMed ID: 3049804
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
